Cross-talk between the thyroid and liver: a new target for nonalcoholic fatty liver disease treatment

World J Gastroenterol. 2013 Dec 7;19(45):8238-46. doi: 10.3748/wjg.v19.i45.8238.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common liver metabolic disease, and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now. Thyroid hormone (TH) and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver. It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions. TRβ1 is predominantly expressed in the brain and adipose tissue and TRβ2 is the major isoform in the liver, kidney and fat. They have different functions and play important roles in lipid metabolism. Recently, there are many studies on the treatment of NAFLD with TH and its analogues. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments. Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues.

Keywords: Nonalcoholic fatty liver disease; Obesity; Thyroid hormone; Thyroid hormone receptor.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Design
  • Dyslipidemias / metabolism
  • Dyslipidemias / physiopathology
  • Fatty Liver / drug therapy
  • Fatty Liver / metabolism*
  • Fatty Liver / physiopathology
  • Humans
  • Lipid Metabolism / drug effects
  • Liver / drug effects
  • Liver / metabolism*
  • Liver / physiopathology
  • Non-alcoholic Fatty Liver Disease
  • Receptors, Thyroid Hormone / agonists
  • Receptors, Thyroid Hormone / metabolism
  • Signal Transduction* / drug effects
  • Thyroid Gland / drug effects
  • Thyroid Gland / metabolism*
  • Thyroid Gland / physiopathology
  • Thyroid Hormones / metabolism
  • Thyroid Hormones / pharmacology

Substances

  • Receptors, Thyroid Hormone
  • Thyroid Hormones